These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30341861)

  • 21. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.
    Chhabra M; Vidyasagar K; Gudi SK; Sharma J; Sharma R; Rashid M
    PLoS One; 2022; 17(7):e0269531. PubMed ID: 35776741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    Vuppalanchi R; Caldwell SH; Pyrsopoulos N; deLemos AS; Rossi S; Levy C; Goldberg DS; Mena EA; Sheikh A; Ravinuthala R; Shaikh F; Bainbridge JD; Parmar DV; Chalasani NP
    J Hepatol; 2022 Jan; 76(1):75-85. PubMed ID: 34487750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The first approved agent in the Glitazar's Class: Saroglitazar.
    Agrawal R
    Curr Drug Targets; 2014 Feb; 15(2):151-5. PubMed ID: 23906191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
    Goyal P; Goyal O; Chhina RS
    J Assoc Physicians India; 2020 Jan; 68(1):97. PubMed ID: 31979903
    [No Abstract]   [Full Text] [Related]  

  • 28. Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.
    Calanna S; Scicali R; Di Pino A; Knop FK; Piro S; Rabuazzo AM; Purrello F
    Nutr Metab Cardiovasc Dis; 2014 Jun; 24(6):670-6. PubMed ID: 24656139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus.
    Artha IMJR; Bhargah A; Dharmawan NK; Pande UW; Triyana KA; Mahariski PA; Yuwono J; Bhargah V; Prabawa IPY; Manuaba IBAP; Rina IK
    Vasc Health Risk Manag; 2019; 15():149-157. PubMed ID: 31239693
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multi-Center, Open-Label, Two-Arm Parallel Group Non-inferiority Randomized Controlled Trial Evaluating the Effect of Pitavastatin, Compared to Atorvastatin, on Glucose Metabolism in Prediabetics with Hypertension and Dyslipidemia: Rationale and Design for the China Hemoglobin A1c Metabolism Protection Union Study (CAMPUS).
    Zhang J; Shao Y; Liu Y; Tao J
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):581-589. PubMed ID: 30187345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diabetes Self-Management Education and Medical Nutrition Therapy: A Multisite Study Documenting the Efficacy of Registered Dietitian Nutritionist Interventions in the Management of Glycemic Control and Diabetic Dyslipidemia through Retrospective Chart Review.
    Marincic PZ; Salazar MV; Hardin A; Scott S; Fan SX; Gaillard PR; Wyatt C; Watson L; Green P; Glover P; Hand M
    J Acad Nutr Diet; 2019 Mar; 119(3):449-463. PubMed ID: 30219311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
    Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
    Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Mitra A
    Cureus; 2020 Jul; 12(7):e9065. PubMed ID: 32782883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
    Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
    Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.